SK82699A3 - Use of glucocorticoids having a minimal systemic effect in the manufacture of a medicament - Google Patents

Use of glucocorticoids having a minimal systemic effect in the manufacture of a medicament Download PDF

Info

Publication number
SK82699A3
SK82699A3 SK826-99A SK82699A SK82699A3 SK 82699 A3 SK82699 A3 SK 82699A3 SK 82699 A SK82699 A SK 82699A SK 82699 A3 SK82699 A3 SK 82699A3
Authority
SK
Slovakia
Prior art keywords
glucocorticoid
medicament
treatment
derivative
daily dose
Prior art date
Application number
SK826-99A
Other languages
English (en)
Slovak (sk)
Inventor
Roger Hallgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of SK82699A3 publication Critical patent/SK82699A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK826-99A 1996-12-20 1997-12-16 Use of glucocorticoids having a minimal systemic effect in the manufacture of a medicament SK82699A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604751A SE9604751D0 (sv) 1996-12-20 1996-12-20 New therapy
PCT/SE1997/002124 WO1998027987A1 (en) 1996-12-20 1997-12-16 New treatment for joint inflammation

Publications (1)

Publication Number Publication Date
SK82699A3 true SK82699A3 (en) 2000-02-14

Family

ID=20405107

Family Applications (1)

Application Number Title Priority Date Filing Date
SK826-99A SK82699A3 (en) 1996-12-20 1997-12-16 Use of glucocorticoids having a minimal systemic effect in the manufacture of a medicament

Country Status (20)

Country Link
US (1) US6432937B1 (sv)
EP (1) EP0957922A1 (sv)
JP (1) JP2001507024A (sv)
KR (1) KR20000069594A (sv)
AU (1) AU5502598A (sv)
BR (1) BR9713975A (sv)
CA (1) CA2274769A1 (sv)
CZ (1) CZ219399A3 (sv)
EE (1) EE9900258A (sv)
HU (1) HUP0000397A3 (sv)
ID (1) ID21763A (sv)
IL (1) IL130485A0 (sv)
IS (1) IS5056A (sv)
NO (1) NO993066L (sv)
NZ (1) NZ336025A (sv)
PL (1) PL334012A1 (sv)
SE (1) SE9604751D0 (sv)
SK (1) SK82699A3 (sv)
TR (1) TR199901413T2 (sv)
WO (1) WO1998027987A1 (sv)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510227A (ja) 2006-11-20 2010-04-02 プレジデント アンド フェロウズ オブ ハーバード カレッジ 痛みおよび痒みの治療方法、組成物およびキット
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP3485881B1 (en) 2009-07-10 2024-03-13 President and Fellows of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
UA112769C2 (uk) 2011-02-18 2016-10-25 Ендо Фармасьютікалз Інк. Аміноінданові сполуки і їх застосування при лікуванні болю
CA2853279C (en) 2011-10-24 2021-03-23 Endo Pharmaceuticals Inc. Cyclohexylamines
BR112016013734A2 (pt) 2013-12-16 2017-08-08 Asana Biosciences Llc Composto, composição farmacêutica, kit, e uso de um composto
MX2018001447A (es) 2015-08-03 2019-02-21 Harvard College Bloqueadores de canal de ion cargado y metodos para su uso.
JP2016193937A (ja) * 2016-08-09 2016-11-17 株式会社エヌ・エル・エー 関節痛緩和組成物および機能性食品、並びに発酵ショウガ及びその製造方法
RU2019112740A (ru) 2016-09-30 2020-11-02 АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи P2x3 и/или p2x2/3 соединения и способы
WO2020185881A1 (en) 2019-03-11 2020-09-17 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2022527438A (ja) 2019-03-11 2022-06-02 ノシオン セラピューティクス,インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
US10927096B2 (en) 2019-03-11 2021-02-23 Nocion Therapeutics, Inc. Ester substituted ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2023500891A (ja) 2019-11-06 2023-01-11 ノシオン セラピューティクス,インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
WO2021091586A1 (en) 2019-11-06 2021-05-14 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11332446B2 (en) 2020-03-11 2022-05-17 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
CA2140660A1 (en) * 1993-06-13 1994-12-22 Uwe R. Juergens Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system

Also Published As

Publication number Publication date
CZ219399A3 (cs) 1999-09-15
HUP0000397A3 (en) 2001-01-29
ID21763A (id) 1999-07-22
AU5502598A (en) 1998-07-17
SE9604751D0 (sv) 1996-12-20
HUP0000397A2 (hu) 2000-10-28
NZ336025A (en) 2001-02-23
PL334012A1 (en) 2000-01-31
NO993066D0 (no) 1999-06-21
IL130485A0 (en) 2000-06-01
CA2274769A1 (en) 1998-07-02
EE9900258A (et) 1999-12-15
TR199901413T2 (xx) 1999-08-23
BR9713975A (pt) 2000-04-11
NO993066L (no) 1999-06-21
JP2001507024A (ja) 2001-05-29
IS5056A (is) 1999-05-27
WO1998027987A1 (en) 1998-07-02
EP0957922A1 (en) 1999-11-24
US6432937B1 (en) 2002-08-13
KR20000069594A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
US6432937B1 (en) Treatment for joint inflammation
Gottlieb et al. Complications of local corticosteroid injections
Brogden et al. Naproxen: a review of its pharmacological properties and therapeutic efficacy and use
CA2519278C (en) Esterified fatty acid composition
JPS6048486B2 (ja) 抗リウマチ剤
CN108354898B (zh) 一种治疗类风湿性关节炎的透皮给药制剂及其制备方法
RU2307651C2 (ru) Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря
US5716646A (en) Methods and compositions for treating arthritis
EP0228239B1 (en) Preparation of a medicament for arthritis and rheumatism
Garcia-Morteo et al. Piroxicam in juvenile rheumatoid arthritis
US7071228B2 (en) Method of treating musculoskeletal and connective tissue inflammations
JPH02134321A (ja) 変形関節炎治療用薬剤を製造するための6―ハロ―4―キノロン化合物およびそれらの薬学的組成物の使用
Fava et al. Single Nightly Administration of Ketoprofen (Orudis®) and Indomethacin Suppositories in the Management of Osteoarthritis: A Double-Blind Trial
MXPA99005663A (en) New treatment for joint inflammation
Brown et al. Double-blind comparison of flurbiprofen and sulindac for the treatment of osteoarthritis
KR0177137B1 (ko) 진통. 염증제지약물
Rhymer et al. A double-blind trial comparing indomethacin sustained release capsules (Indocid-R) with indomethacin capsules in patients with rheumatoid arthritis
Solomon, L. & Abrams Bumadizone calcium in the treatment of rheumatoid arthritis
CN115869293A (zh) 莱菔素用于制备治疗类风湿性关节炎的药物的用途
Nyfos A comparative clinical study of a new antirheumatic agent, tolfenamic acid (Clotam), and Phenylbutazone in rheumatoid arthritis
Frankhof Controlled-release naproxen compared with isoxicam in patients with osteoarthritis
Rothwell Efficacy and safety of a non-acetylated salicylate, choline magnesium trisalicylate, in the treatment of rheumatoid arthritis
Aylward et al. Treatment of rheumatoid arthritis with tolmetin: a comparison with alclofenac
Janke et al. Sulindac versus piroxicam in the treatment of osteoarthritis
Pavelka et al. Experience with high doses of ibuprofen in the long-term treatment of rheumatoid arthritis